Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 128.21 B
The data is delayed by 15 minutes.
Description: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company?s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||1.67 B||EPS||2.51||EPS Growth - 4 Quarters||-704.03%||EPS Growth - Q/Q||-233.04%|
|EPS Growth - Y/Y||-255.12%||Sales Growth - 4 Quarters||6.17%||Sales Growth - Q/Q||3.02%||P/E||21.7|
|P/E To EPS Growth||0.28||P/S||7.83||P/BV||8.48||Price/Cash Per Share||23.41|
|Price/Free Cash Flow||48.9||ROA||5.6%||ROE||11.84%||ROI||7.56%|
|Current Ratio||1.76||Quick Ratio||1.58||Long Term Debt/Equity||1.18||Debt Ratio||0.49|
|Gross Margin||76.6%||Operating Margin||14.94%||Net Profit Margin||10.93%||Dividend Payout Ratio||-136.15%|
|Cash From Financing Activities||-1.57 B||Cash From Investing Activities||-526 M||Cash From Operating Activities||697 M||Gross Profit||3.18 B|
|Net Profit||-130 M||Operating Profit||45 M||Total Assets||31.95 B||Total Current Assets||13.06 B|
|Total Current Liabilities||7.44 B||Total Debt||7.37 B||Total Liabilities||16.83 B||Total Revenue||4.16 B|
|High 52 week||68.98||Low 52 week||44.62||Last close||46.85||Last change||-0.57%|
|RSI||53.8||Average true range||0.98||Beta||0.67||Volume||5.04 M|
|Simple moving average 20 days||0.65%||Simple moving average 50 days||-0.72%||Simple moving average 200 days||-10.35%|
|Performance Week||-0.34%||Performance Month||2.29%||Performance Quart||-8.53%||Performance Half||-10.11%|
|Performance Year||-25.2%||Performance Year-to-date||-9.05%||Volatility daily||1.34%||Volatility weekly||3%|
|Volatility monthly||6.16%||Volatility yearly||21.32%||Relative Volume||180.93%||Average Volume||18.66 M|
|New High||New Low|
2019-06-21 10:01:02 | 3 Big Biotechs Hold Growth Potential in Second Half of 2019
2019-06-21 09:07:01 | Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod
2019-06-21 08:00:00 | Where Will bluebird bio Be in 1 Year?
2019-06-20 09:05:00 | What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?
2019-06-19 17:45:00 | This would be the worst-case scenario for health companies, according to UBS
2019-06-19 09:06:01 | Big Drugmakers That May Tread the M&A Path After Pfizer
2019-06-19 09:00:01 | Bristol-Myers BMY Upgraded to Buy: What Does It Mean for the Stock?
2019-06-18 17:45:09 | Bristol-Myers Squibb BMY Stock Sinks As Market Gains: What You Should Know
2019-06-18 14:11:37 | 2019 Business of Pride honorees: Bristol-Myers Squibb
2019-06-18 13:00:05 | Top Analyst Reports for Broadcom, Amgen & NVIDIA
2019-06-18 09:51:01 | Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio
2019-06-17 09:35:04 | Pfizer Expands in Cancer With $10.6 Billion Deal for Array
2019-06-16 09:00:00 | Is It Too Late to Buy Celgene Stock?
2019-06-14 13:52:24 | Should Bristol-Myers Squibb Company NYSE:BMY Be Part Of Your Dividend Portfolio?
2019-06-14 12:06:04 | 3 Big Pharma Stocks to Buy Right Now
2019-06-14 08:29:12 | Mallinckrodt Presents Encouraging Data on Acthar Gel for RA
2019-06-14 06:59:00 | Bristol-Myers Squibb Presents Updated Efficacy Data from Phase 2 Trial of Empliciti elotuzumab Plus Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma RRMM
2019-06-13 17:40:09 | Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris
2019-06-13 16:38:00 | Bristol-Myers Squibb Announces Dividend
2019-06-13 16:30:00 | New Mechanistic Study Explores the Relationship Between a Key Genetic Marker and Clinical Efficacy of ORENCIA® abatacept or adalimumab in Moderate-to-Severe Early Rheumatoid Arthritis Patients
2019-06-13 09:19:00 | Price target on Bristol-Myers stock cut to $51 at UBS
2019-06-12 18:33:10 | Roche's Rituxan Gets Priority Review for Blood Disorder
2019-06-12 18:21:10 | Novartis Reports Data on Cosentyx for Psoriatic Arthritis
2019-06-12 17:45:09 | Bristol-Myers Squibb BMY Gains As Market Dips: What You Should Know
2019-06-12 10:19:02 | Zacks.com featured highlights include: CDW, Bristol-Myers, Celgene, PepsiCo and Northrop
2019-06-12 09:15:01 | Bristol-Myers Squibb BMY is a Top Dividend Stock Right Now: Should You Buy?
2019-06-12 08:28:12 | Boost Your Portfolio's Health With These 3 Big Drug Stocks
2019-06-11 18:16:10 | Insys Down on Bankruptcy News Amid Increasing Legal Expenses
2019-06-11 08:53:12 | Merck MRK to Buy Private Biotech Tilos for Up to $773M
2019-06-11 08:34:12 | Top 5 ROE Stocks to Buy as US-Mexico Trade Concerns Abate
2019-06-11 08:00:32 | See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
2019-06-10 12:34:04 | Sanofi SNY in Focus: Stock Moves 5.5% Higher
2019-06-10 09:57:01 | The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca
2019-06-10 08:00:11 | See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
2019-06-07 13:06:26 | 2 Dividend Stocks to Buy That Are Better Than 3M Stock
2019-06-07 12:05:14 | Seth Klarman's Favorite Biotech Positions
2019-06-07 10:21:02 | Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache
2019-06-07 09:09:01 | Novartis Appoints New Pharma Unit Head, Gives Other Updates
2019-06-06 19:17:48 | Management Changes Intended to Boost Bristol-Myers Squibb After Celgene Deal
2019-06-06 17:45:09 | Bristol-Myers Squibb BMY Stock Sinks As Market Gains: What You Should Know
2019-06-06 16:56:08 | Celgene & Acceleron's BLA for Luspatercept Accepted by FDA
2019-06-06 16:41:08 | Mallinckrodt Down After Agreement with DOJ for Litigation
2019-06-06 15:13:05 | 5 Healthcare Stocks to Pick Up From the Wreckage
2019-06-06 13:55:00 | Top 5 Stocks in the Fight Against Cancer
2019-06-06 09:09:01 | Was ASCO Quieter for Big Drug/Biotech Stocks This Year?
2019-06-06 09:00:15 | A Look at Bristol-Myers Squibb’s Near-Term Product Launches
2019-06-06 06:59:00 | Bristol-Myers Squibb to Announce Results for Second Quarter 2019 on July 25, 2019
2019-06-05 16:30:04 | The Celgene Merger Looks Secure — So Why Is Bristol Under Pressure?